Expedition Medicines, Inc.

Expedition Medicines, Inc. is a US-based biopharmaceutical company focused on developing therapeutic solutions that utilize covalent chemistry and artificial intelligence to address unmet medical needs. Founded in 2022 and headquartered in Cambridge, US, Expedition Medicines, Inc. specializes in creating innovative drugs targeting specific proteins.

The company secured its first deal in 2025, raising USD 50 mn in Series A funding led by Flagship Pioneering, which has been pivotal for their growth strategy. Expedition Medicines specializes in developing innovative therapeutic solutions that leverage the intersection of covalent chemistry and artificial intelligence. The company focuses on addressing unmet medical needs by creating new medicines for patients whose conditions are driven by specific proteins, which current medications cannot effectively target. Their primary offerings incorporate advanced technologies, including intelligent systems that learn from experimental data, enabling the design of novel drug candidates.

The customer base includes pharmaceutical companies and biotechnology firms seeking solutions to enhance their drug development processes. Expedition Medicines operates primarily within the North American and European markets, aiming to serve healthcare providers and patients requiring tailored therapeutic interventions. Revenue generation at Expedition Medicines is structured around strategic partnerships and collaborations with other organizations in the pharmaceutical sector. The company engages in B2B transactions, partnering with established drug manufacturers and research institutions to develop and commercialize its proprietary technologies and drug candidates.

Revenue is derived from contractual agreements that include milestone payments tied to drug development progress, as well as potential royalties from product sales upon successful commercialization. Expedition Medicines also engages in collaborative research agreements, which may involve shared costs and resources for joint development projects, thereby enhancing its revenue streams while fostering innovation in drug discovery. In October 2025, Expedition Medicines, Inc. raised USD 50 mn in Series A funding, led by Flagship Pioneering.

This funding will be utilized to scale its quantum chemistry platform, accelerate its discovery program, and support its exploration agreement. The company plans to launch new products designed to target specific unmet medical needs and is looking to expand into new markets, particularly in Europe and North America, by 2026.